amyloidosis
Let an agent give general, sourced information about amyloidosis, route urgent symptoms to emergency care, point to specialist centres and support groups, and avoid personal medical advice.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
written by Claude from model knowledge without web access - no source was read, every claim is a lead to verify
Researched by: Claude
Purpose and description
Let an agent give general, sourced information about amyloidosis, route urgent symptoms to emergency care, point to specialist centres and support groups, and avoid personal medical advice.
A group of diseases in which abnormally folded proteins called amyloid build up in organs and tissues, such as AL amyloidosis from light chains, ATTR amyloidosis from transthyretin, hereditary or wild-type, and AA amyloidosis linked to chronic inflammation; effects depend on the organs involved, such as the heart, kidneys and nerves.
What it is for: A group of rare diseases relevant to diagnosis, specialist care and support.
It can be find general information about amyloidosis types; recognise urgent symptoms; find specialist centres; find patient support organisations.
Distinguishing features
Misfolded protein deposits
Many types
Can affect several organs
Treated at specialist centres
What it looks like
Not visible directly; diagnosed by biopsy, imaging and laboratory tests.
How it is recognised
Amyloid deposits in tissue samples
Types named by the precursor protein
Alzheimer amyloid plaques are a distinct topic
Related models
is a kind of - category
is caused by - mechanism
can affect - organs
is treated at - care
In practice
Families and kinds
AL amyloidosis
ATTR amyloidosis (hereditary and wild-type)
AA amyloidosis
localised amyloidosis
cutaneous amyloidosis
Standards and regulation
Clinical guidelines on amyloidosis
Medicines regulation for new therapies
Genetic counselling standards for hereditary forms
Failure modes and hazards
Delayed diagnosis
Agents giving treatment advice
Confusing types with different treatments
Also called
Where this came from
wikidata · CC0 1.0
Also registered as vr.tr.amyloidosis
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 4 bundles · 8 layers · 8 findings · 16 questions.
Urgent Urgent symptoms.
Safety comes first.
Heart
Cardiac symptoms.
Heart
Cardiac symptoms.
- Is there chest pain, severe breathlessness or fainting? boundary
- Should emergency services be called now? action
Review
Seeing a doctor.
Review
Medical review.
- Are there persistent symptoms such as swelling, numbness or frothy urine that need review? boundary
- Should the person see their doctor promptly? action
Information General facts.
Sourced information only.
Types
Kinds.
Types
Types.
- What do specialist centres say about this type of amyloidosis? provenance
- How is it diagnosed in general terms? definition
Personal
Personal questions.
Personal
Personal advice limits.
- Is the user asking about their own diagnosis, treatment or prognosis? boundary
- How should the agent refer them to their specialist team? action
Care Services.
Specialist care matters.
Centres
Specialist centres.
Centres
Specialist centres.
- Which specialist amyloidosis centres serve this region? provenance
- How are referrals made? provenance
Genetics
Hereditary forms.
Genetics
Hereditary forms.
- Should relatives consider genetic counselling for hereditary ATTR amyloidosis? provenance
- How can they access it? action
Support Patients and families.
Support helps.
Groups
Support organisations.
Groups
Support organisations.
- Which patient organisations support people with amyloidosis? provenance
- Do they run helplines? provenance
Trials
Clinical trials.
Trials
Clinical trials.
- Which official registries list amyloidosis trials? provenance
- Who can discuss eligibility? action
What the second pass must settle
- Should each type be a separate entry?
- How should specialist centres be linked?
- How should new therapies be tracked?